NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts

被引:253
作者
Marlein, Christopher R. [1 ]
Zaitseva, Lyubov [1 ]
Piddock, Rachel E. [1 ]
Robinson, Stephen D. [2 ]
Edwards, Dylan R. [1 ]
Shafat, Manar S. [1 ]
Zhou, Zhigang [1 ]
Lawes, Matthew [3 ]
Bowles, Kristian M. [1 ,3 ]
Rushworth, Stuart A. [1 ]
机构
[1] Univ East Anglia, Norwich Med Sch, Norwich Res Pk, Norwich, Norfolk, England
[2] Univ East Anglia, Sch Biol Sci, Norwich Res Pk, Norwich, Norfolk, England
[3] Norfolk & Norwich Univ Hosp NHS Trust, Dept Haematol, Norwich, Norfolk, England
关键词
ACUTE MYELOID-LEUKEMIA; TUNNELING NANOTUBES; REACTIVE OXYGEN; CANCER-CELLS; DNA; ROS; MICROENVIRONMENT; ACTIVATION; EXPRESSION; MIGRATION;
D O I
10.1182/blood-2017-03-772939
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Improvements in the understanding of the metabolic cross-talk between cancer and itsmicroenvironment are expected to lead to novel therapeutic approaches. Acute myeloid leukemia (AML) cells have increased mitochondria compared with nonmalignant CD34(+) hematopoietic progenitor cells. Furthermore, contrary to the Warburg hypothesis, AML relies on oxidative phosphorylation to generate adenosine triphosphate. Here we report that in human AML, NOX2generates superoxide, which stimulates bonemarrow stromal cells (BMSC) toAMLblast transfer of mitochondria through AML-derived tunneling nanotubes. Moreover, inhibition of NOX2 was able to prevent mitochondrial transfer, increase AML apoptosis, and improve NSG AMLmouse survival. Although mitochondrial transfer fromBMSC to nonmalignant CD34(+) cells occurs in response tooxidativestress, NOX2inhibitionhadnodetectable effectonnonmalignantCD34(+) cellsurvival. Taken together, we identify tumor-specific dependence on NOX2-driven mitochondrial transfer as a novel therapeutic strategy in AML.
引用
收藏
页码:1649 / 1660
页数:12
相关论文
共 35 条
  • [11] Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia
    Matsunaga, T
    Takemoto, N
    Sato, T
    Takimoto, R
    Tanaka, I
    Fujimi, A
    Akiyama, TH
    Kuroda, H
    Kawano, Y
    Kobune, M
    Kato, J
    Hirayama, Y
    Sakamaki, S
    Kohda, K
    Miyake, K
    Niitsu, Y
    [J]. NATURE MEDICINE, 2003, 9 (09) : 1158 - 1165
  • [12] Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy
    Moschoi, Ruxanda
    Imbert, Veronique
    Nebout, Marielle
    Chiche, Johanna
    Mary, Didier
    Prebet, Thomas
    Saland, Estelle
    Castellano, Remy
    Pouyet, Laurent
    Collette, Yves
    Vey, Norbert
    Chabannon, Christian
    Recher, Christian
    Sarry, Jean-Emmanuel
    Alcor, Damien
    Peyron, Jean-Francois
    Griessinger, Emmanuel
    [J]. BLOOD, 2016, 128 (02) : 253 - 264
  • [13] Preferential transfer of mitochondria from endothelial to cancer cells through tunneling nanotubes modulates chemoresistance
    Pasquier, Jennifer
    Guerrouahen, Bella S.
    Al Thawadi, Hamda
    Ghiabi, Pegah
    Maleki, Mahtab
    Abu-Kaoud, Nadine
    Jacob, Arthur
    Mirshahi, Massoud
    Galas, Ludovic
    Rafii, Shahin
    Le Foll, Frank
    Rafii, Arash
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11
  • [14] PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment
    Piddock, R. E.
    Loughran, N.
    Marlein, C. R.
    Robinson, S. D.
    Edwards, D. R.
    Yu, S.
    Pillinger, G. E.
    Zhou, Z.
    Zaitseva, L.
    Auger, M. J.
    Rushworth, S. A.
    Bowles, K. M.
    [J]. BLOOD CANCER JOURNAL, 2017, 7 : e539 - e539
  • [15] B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment
    Polak, Roel
    de Rooij, Bob
    Pieters, Rob
    den Boer, Monique L.
    [J]. BLOOD, 2015, 126 (21) : 2404 - 2414
  • [16] How I treat acute myeloid leukemia
    Rowe, Jacob M.
    Tallman, Martin S.
    [J]. BLOOD, 2010, 116 (17) : 3147 - 3156
  • [17] Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells
    Rushworth, Stuart A.
    Pillinger, Genevra
    Abdul-Aziz, Amina
    Piddock, Rachel
    Shafat, Manar S.
    Murray, Megan Y.
    Zaitseva, Lyubov
    Lawes, Matthew J.
    MacEwan, David J.
    Bowles, Kristian M.
    [J]. LANCET HAEMATOLOGY, 2015, 2 (05): : E204 - E211
  • [18] The high Nrf2 expression in human acute myeloid leukemia is driven by NF-κB and underlies its chemo-resistance
    Rushworth, Stuart A.
    Zaitseva, Lyubov
    Murray, Megan Y.
    Shah, Niraj M.
    Bowles, Kristian M.
    MacEwan, David J.
    [J]. BLOOD, 2012, 120 (26) : 5188 - 5198
  • [19] Nanotubular highways for intercellular organelle transport
    Rustom, A
    Saffrich, R
    Markovic, I
    Walther, P
    Gerdes, HH
    [J]. SCIENCE, 2004, 303 (5660) : 1007 - 1010
  • [20] Genomic instability in myeloid malignancies: Increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair
    Sallmyr, Annahita
    Fan, Jinshui
    Rassool, Feyruz Virgilia
    [J]. CANCER LETTERS, 2008, 270 (01) : 1 - 9